JP2023542290A - 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 - Google Patents
濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 Download PDFInfo
- Publication number
- JP2023542290A JP2023542290A JP2023515677A JP2023515677A JP2023542290A JP 2023542290 A JP2023542290 A JP 2023542290A JP 2023515677 A JP2023515677 A JP 2023515677A JP 2023515677 A JP2023515677 A JP 2023515677A JP 2023542290 A JP2023542290 A JP 2023542290A
- Authority
- JP
- Japan
- Prior art keywords
- administered
- bispecific antibody
- day
- dose
- cycles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076792P | 2020-09-10 | 2020-09-10 | |
| US63/076,792 | 2020-09-10 | ||
| PCT/EP2021/075020 WO2022053656A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542290A true JP2023542290A (ja) | 2023-10-06 |
| JP2023542290A5 JP2023542290A5 (cg-RX-API-DMAC7.html) | 2024-09-18 |
Family
ID=77914293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515677A Pending JP2023542290A (ja) | 2020-09-10 | 2021-09-10 | 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230357440A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4210743A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023542290A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230066391A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116406293A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021341509A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004216A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3189883A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301098A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002544A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022053656A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102813816B1 (ko) * | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| CN107660214B (zh) * | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| KR20230008775A (ko) | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
| CN116437956A (zh) | 2020-09-10 | 2023-07-14 | 健玛保 | 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体 |
| WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| WO2022053657A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| IL301086A (en) | 2020-09-10 | 2023-05-01 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| US20230382993A1 (en) * | 2022-05-24 | 2023-11-30 | Provention Bio, Inc. | Methods and compositions for preventing or delaying type 1 diabetes |
| EP4695293A1 (en) * | 2023-04-13 | 2026-02-18 | Genmab A/S | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 |
| IL324479A (en) * | 2023-05-15 | 2026-01-01 | Genmab As | Methods for treating CD20-expressing B-cell cancers |
| WO2024236031A1 (en) | 2023-05-15 | 2024-11-21 | Genmab A/S | Highly purified epcoritamab compositions |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019155008A1 (en) * | 2018-02-09 | 2019-08-15 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| WO2008145141A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| IN2014CN03887A (cg-RX-API-DMAC7.html) | 2011-10-27 | 2015-10-16 | Genmab As | |
| WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| CN104936985A (zh) | 2013-02-26 | 2015-09-23 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| KR102813816B1 (ko) | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| BR112016000666A2 (pt) | 2013-07-12 | 2017-10-03 | Zymeworks Inc | Constructos de ligação de antígeno cd3 e cd19 biespecíficos |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2809455T3 (es) | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| CN107660214B (zh) * | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| US20160199399A1 (en) | 2015-01-09 | 2016-07-14 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness in cancer patients |
| CN104922688A (zh) | 2015-02-10 | 2015-09-23 | 昆明贵研药业有限公司 | 奥沙利铂的环糊精复合物及制备方法 |
| WO2017210485A1 (en) | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| EP3541843A1 (en) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| AU2018259078B2 (en) | 2017-04-27 | 2021-10-07 | Astrazeneca Ab | C5-anilinoquinazoline compounds and their use in treating cancer |
| EP4427810A3 (en) | 2018-11-30 | 2024-12-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| AU2020328195A1 (en) * | 2019-08-15 | 2022-03-03 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against CD3 and CD20 and their uses |
| KR20230008775A (ko) * | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
| WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| WO2022053657A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| CN116437956A (zh) | 2020-09-10 | 2023-07-14 | 健玛保 | 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体 |
| IL301086A (en) | 2020-09-10 | 2023-05-01 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| BR112023004319A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma difuso de grandes células b |
-
2021
- 2021-09-10 JP JP2023515677A patent/JP2023542290A/ja active Pending
- 2021-09-10 US US18/025,205 patent/US20230357440A1/en active Pending
- 2021-09-10 EP EP21777654.1A patent/EP4210743A1/en active Pending
- 2021-09-10 KR KR1020237011603A patent/KR20230066391A/ko active Pending
- 2021-09-10 IL IL301098A patent/IL301098A/en unknown
- 2021-09-10 BR BR112023004216A patent/BR112023004216A2/pt unknown
- 2021-09-10 AU AU2021341509A patent/AU2021341509A1/en active Pending
- 2021-09-10 CN CN202180069855.8A patent/CN116406293A/zh active Pending
- 2021-09-10 CA CA3189883A patent/CA3189883A1/en active Pending
- 2021-09-10 MX MX2023002544A patent/MX2023002544A/es unknown
- 2021-09-10 WO PCT/EP2021/075020 patent/WO2022053656A1/en not_active Ceased
- 2021-12-21 US US17/558,404 patent/US11535679B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019155008A1 (en) * | 2018-02-09 | 2019-08-15 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
Non-Patent Citations (4)
| Title |
|---|
| BLOOD, vol. Vol. 114, No. 22, Abstract No. 405, JPN6025032022, 2009, ISSN: 0005874615 * |
| BLOOD, vol. Vol. 134, Suppl. 1, Abstract No. 4066, JPN6025032024, 2019, ISSN: 0005874614 * |
| J CLIN ONCOL, MEETING ABSTRACT: 2020 ANNUAL MEETING I, vol. Vol. 38, No. 15, Suppl., JPN6025032023, 25 May 2020 (2020-05-25), ISSN: 0005874617 * |
| ONCOLOGIST, vol. 23, JPN7025003471, 2018, pages 454 - 460, ISSN: 0005874616 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230066391A (ko) | 2023-05-15 |
| IL301098A (en) | 2023-05-01 |
| AU2021341509A1 (en) | 2023-04-13 |
| CA3189883A1 (en) | 2022-03-17 |
| MX2023002544A (es) | 2023-03-14 |
| CN116406293A (zh) | 2023-07-07 |
| US20230357440A1 (en) | 2023-11-09 |
| EP4210743A1 (en) | 2023-07-19 |
| BR112023004216A2 (pt) | 2023-04-11 |
| US20220112300A1 (en) | 2022-04-14 |
| US11535679B2 (en) | 2022-12-27 |
| WO2022053656A1 (en) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11535679B2 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma | |
| US11608383B2 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma | |
| US11845805B2 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma | |
| US11858995B2 (en) | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia | |
| JP2023542092A (ja) | びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 | |
| JP2023542291A (ja) | びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 | |
| US20240368297A1 (en) | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 | |
| HK40096389A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma | |
| HK40096702A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma | |
| HK40096765A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240909 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240909 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250731 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250805 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260602 |